| Size | Price | Stock | Qty |
|---|---|---|---|
| 25g |
|
||
| Other Sizes |
| Targets |
Microbial Metabolite Human Endogenous Metabolite
6-Hydroxynicotinic acid does not have a specific pharmacological target as it is an endogenous metabolite. As a metabolite of nicotinamide, it is involved in nicotinic acid metabolism. It stimulates adrenocortical secretion. Its "target" in research is the study of nicotinic acid metabolism and endocrine function. |
|---|---|
| ln Vitro |
In vitro, 6-Hydroxynicotinic acid is used as a building block in chemical synthesis. It is a metabolite of nicotinamide. Its "activity" is reflected in its chemical properties as a nicotinic acid derivative and its role as a metabolite.
|
| ln Vivo |
In vivo, 6-Hydroxynicotinic acid is a human urinary metabolite and a mouse metabolite. It stimulates adrenocortical secretion. It is not a therapeutic agent but is studied in the context of nicotinic acid metabolism and endocrine function.
|
| Enzyme Assay |
In vitro enzyme assays with 6-Hydroxynicotinic acid typically involve studying enzymes involved in nicotinic acid metabolism such as nicotinate hydroxylases. The compound can be used as a substrate or product in assays to characterize enzyme activity. Standard assays involve incubating with enzyme preparations and analyzing products by HPLC or LC-MS.
|
| Cell Assay |
6-Hydroxynicotinic acid is not typically used in cell culture experiments as a bioactive compound for treating cells. However, it may be employed in studies investigating nicotinic acid metabolism or as a standard for analytical method development. Its primary use is as a research chemical and metabolite.
|
| Animal Protocol |
In vivo animal experiments with 6-Hydroxynicotinic acid typically involve measuring its levels in urine or other biological samples as a metabolite. Animal models are used to study changes in 6-hydroxynicotinic acid levels and their correlation with nicotinic acid metabolism or endocrine function.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of 6-Hydroxynicotinic acid reflect its role as a metabolite. It is produced from nicotinamide and excreted in urine. Its levels in biological samples reflect nicotinic acid metabolism. Specific PK data are not available as it is a metabolite rather than a drug.
|
| Toxicity/Toxicokinetics |
6-Hydroxynicotinic acid has a low toxicity profile as a naturally occurring metabolite. For research use, standard laboratory safety practices are sufficient. It is not considered a hazardous substance. Comprehensive toxicology studies have not been published for this compound.
|
| Additional Infomation |
6-Hydroxynicotinic acid (HNA) is a monohydroxypyridine, a 6-hydroxy derivative of nicotinic acid. It is found in mouse and human urine and in Arabidopsis thaliana as a metabolite. Its function is related to nicotinic acid; it is the conjugate acid of 6-hydroxynicotinic acid ester (1-). Studies have reported the presence of HNA in Arabidopsis thaliana and Caenorhabditis elegans.
6-Hydroxynicotinic acid is a monohydroxypyridine that is the 6-hydroxy derivative of nicotinic acid. It is a metabolite of nicotinamide and has a role as a mouse metabolite, a human urinary metabolite, and an Arabidopsis thaliana metabolite. It stimulates adrenocortical secretion. The compound is not a drug and has no therapeutic indications. |
| Molecular Formula |
C6H5NO3
|
|---|---|
| Molecular Weight |
139.11
|
| Exact Mass |
139.026
|
| CAS # |
5006-66-6
|
| PubChem CID |
72924
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
488.8±30.0 °C at 760 mmHg
|
| Melting Point |
310 °C
|
| Flash Point |
249.4±24.6 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.626
|
| LogP |
-0.96
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
10
|
| Complexity |
239
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=O)NC=C1C(=O)O
|
| InChi Key |
BLHCMGRVFXRYRN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H5NO3/c8-5-2-1-4(3-7-5)6(9)10/h1-3H,(H,7,8)(H,9,10)
|
| Chemical Name |
6-oxo-1H-pyridine-3-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 33.33 mg/mL (239.59 mM)
H2O: 2 mg/mL (14.38 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.43 mg/mL (10.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.43 mg/mL (10.28 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.43 mg/mL (10.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 1 mg/mL (7.19 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.1886 mL | 35.9428 mL | 71.8856 mL | |
| 5 mM | 1.4377 mL | 7.1886 mL | 14.3771 mL | |
| 10 mM | 0.7189 mL | 3.5943 mL | 7.1886 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
